Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease

Neuroscience

Volumn 246, Issue , 2013, Pages 382-390

  St Laurent, R ^a,c   O'Brien, L M ^a,b   Ahmad, S T ^a  

^a Health Services and Department of Biology   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Drosophila disease models; HDAC inhibitors; Neurodegenerative disease; Parkinson's disease; Rotenone; Sodium butyrate

Indexed keywords

BUTYRIC ACID; DOPAMINE; HISTONE DEACETYLASE; MESSENGER RNA; ROTENONE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR SIN3A; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOPAMINE BRAIN LEVEL; DROSOPHILA; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GENE SILENCING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOSS OF FUNCTION MUTATION; MASS SPECTROMETRY; MORTALITY; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; WILD TYPE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BUTYRIC ACID; DISEASE MODELS, ANIMAL; DROSOPHILA; HISTONE DEACETYLASE INHIBITORS; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; PESTICIDES; ROTENONE;

EID: 84879420897     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.04.037     Document Type: Article

References (40)

1. Akiba Y., Cave J.W., Akiba N., Langley B., Ratan R.R., Baker H. Histone deacetylase inhibitors de-repress tyrosine hydroxylase expression in the olfactory bulb and rostral migratory stream. Biochem Biophys Res Commun 2010, 393:673-677.
2. Bayersdorfer F., Voigt A., Schneuwly S., Botella J.A. Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson's disease. Neurobiol Dis 2010, 40:113-119.
3. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 2009, 34:279-290.
4. Chuang D.M., Leng Y., Marinova Z., Kim H.J., Chiu C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009, 32:591-601.
5. Cicchetti F., Drouin-Ouellet J., Gross R.E. Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?. Trends Pharmacol Sci 2009, 30:475-483.
6. Coulom H., Birman S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J Neurosci 2004, 24:10993-10998.
7. D'Souza A., Onem E., Patel P., La Gamma E.F., Nankova B.B. Valproic acid regulates catecholaminergic pathways by concentration-dependent threshold effects on TH mRNA synthesis and degradation. Brain Res 2009, 1247:1-10.
8. Egorin M.J., Yuan Z.M., Sentz D.L., Plaisance K., Eiseman J.L. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol 1999, 43:445-453.
9. Emdadul Haque M., Asanuma M., Higashi Y., Miyazaki I., Tanaka K., Ogawa N. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta 2003, 1619:39-52.
10. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature 2000, 404:394-398.
11. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003, 23:9418-9427.
12. Haque M.E., Asanuma M., Higashi Y., Miyazaki I., Tanaka K., Ogawa N. Overexpression of Cu-Zn superoxide dismutase protects neuroblastoma cells against dopamine cytotoxicity accompanied by increase in their glutathione level. Neurosci Res 2003, 47:31-37.
13. Hayakawa T., Nakayama J. Physiological roles of class I HDAC complex and histone demethylase. J Biomed Biotechnol 2011, 2011:129383.
14. Hisahara S., Shimohama S. Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis 2010, 2011:951709.
15. Hosamani R., Ramesh S.R., Muralidhara, Attenuation of rotenone-induced mitochondrial oxidative damage and neurotoxicty in Drosophila melanogaster supplemented with creatine. Neurochem Res 2010, 35:1402-1412.
16. +-mediated toxicity by histone deacetylase inhibition. Brain Res 2010, 1354:172-178.
17. Kidd S.K., Schneider J.S. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 2011, 194:189-194.
18. Kim H.S., Park J.S., Hong S.J., Woo M.S., Kim S.Y., Kim K.S. Regulation of the tyrosine hydroxylase gene promoter by histone deacetylase inhibitors. Biochem Biophys Res Commun 2003, 312:950-957.
19. Kontopoulos E., Parvin J.D., Feany M.B. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 2006, 15:3012-3023.
20. Le Couteur D.G., Muller M., Yang M.C., Mellick G.D., McLean A.J. Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease. Rev Environ Health 2002, 17:51-64.
21. Lewis E.J., Tank A.W., Weiner N., Chikaraishi D.M. Regulation of tyrosine hydroxylase mRNA by glucocorticoid and cyclic AMP in a rat pheochromocytoma cell line. Isolation of a cDNA clone for tyrosine hydroxylase mRNA. J Biol Chem 1983, 258:14632-14637.
22. Mai A., Rotili D., Valente S., Kazantsev A.G. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des 2009, 15:3940-3957.
23. McDonald P., Maizi B.M., Arking R. Chemical regulation of mid- and late-life longevities in Drosophila. Exp Gerontol. 2013, 48:240-249.
24. Nankova B.B., Chua J., Mishra R., Kobasiuk C.D., La Gamma E.F. Nicotinic induction of preproenkephalin and tyrosine hydroxylase gene expression in butyrate-differentiated rat PC12 cells: a model for adaptation to gut-derived environmental signals. Pediatr Res 2003, 53:113-118.
25. Neckameyer W.S., Quinn W.G. Isolation and characterization of the gene for Drosophila tyrosine hydroxylase. Neuron 1989, 2:1167-1175.
26. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999, 22:123-144.
27. Pallos J., Bodai L., Lukacsovich T., Purcell J.M., Steffan J.S., Thompson L.M., Marsh J.L. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 2008, 17:3767-3775.
28. Poewe W., Antonini A., Zijlmans J.C., Burkhard P.R., Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 2010, 5:229-238.
29. Saha R.N., Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 2006, 13:539-550.
30. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003, 23:10756-10764.
31. Shimazu T., Hirschey M.D., Newman J., He W., Shirakawa K., Le Moan N., Grueter C.A., Lim H., Saunders L.R., Stevens R.D., Newgard C.B., Farese R.V., de Cabo R., Ulrich S., Akassoglou K., Verdin E. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013, 339:211-214.
32. Spivey A. Rotenone and paraquat linked to Parkinson's disease: human exposure study supports years of animal studies. Environ Health Perspect 2011, 119:A259.
33. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., Kazantsev A., Schmidt E., Zhu Y.Z., Greenwald M., Kurokawa R., Housman D.E., Jackson G.R., Marsh J.L., Thompson L.M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
34. Sun J., Tower J. FLP recombinase-mediated induction of Cu/Zn-superoxide dismutase transgene expression can extend the life span of adult Drosophila melanogaster flies. Mol Cell Biol 1999, 19:216-228.
35. Tabachnick B.G., Fidell L.S. Experimental design using ANOVA 2007, Duxbury Press, Belmont.
36. Testa C.M., Sherer T.B., Greenamyre J.T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 2005, 134:109-118.
37. Thanvi B., Lo N., Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 2007, 83:384-388.
38. Wu X., Chen P.S., Dallas S., Wilson B., Block M.L., Wang C.C., Kinyamu H., Lu N., Gao X., Leng Y., Chuang D.M., Zhang W., Lu R.B., Hong J.S. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 2008, 11:1123-1134.
39. Xiong N., Huang J., Zhang Z., Zhang Z., Xiong J., Liu X., Jia M., Wang F., Chen C., Cao X., Liang Z., Sun S., Lin Z., Wang T. Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease. PloS One 2009, 4:e7878.
40. Yarali A., Krischke M., Michels B., Saumweber T., Mueller M.J., Gerber B. Genetic distortion of the balance between punishment and relief learning in Drosophila. J Neurogenet 2009, 23:235-247.